Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1990 Sep-Oct;63(5):361–369.

Blood protein derivative viral safety: observations and analysis.

B Horowitz 1
PMCID: PMC2589360  PMID: 1963504

Abstract

The well-documented viral safety of albumin arises from several factors operating in concert, including virus removal during preparation, immune neutralization, serendipitous inactivation, virus sterilization through pasteurization. Safety with respect to HBV transmission was achieved even prior to the development of sensitive screening tests for HBsAg, as can be predicted given the initial virus load and the influence of factors affecting removal and inactivation. Coagulation factor concentrates, as traditionally prepared, are known to have transmitted the viral agents of hepatitis and AIDS with high frequency. Application of virucidal procedures to these concentrates, in some cases, appears to have eliminated virus transmission, raising the question as to whether absolute safety has now been achieved. Clinical proof of absolute safety is made difficult by the small number of eligible patients who can be monitored, lengthy and expensive monitoring procedures, and opportunity for transmission of virus by product-independent routes. Based on viral load analysis, modern coagulation factor concentrates are predicted to have the same probability of freedom from HIV, HBV, and HCV transmission as that exhibited by albumin.

Full text

PDF
361

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aach R. D., Szmuness W., Mosley J. W., Hollinger F. B., Kahn R. A., Stevens C. E., Edwards V. M., Werch J. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med. 1981 Apr 23;304(17):989–994. doi: 10.1056/NEJM198104233041701. [DOI] [PubMed] [Google Scholar]
  2. Almeida J. D. Individual morphological variations seen in Australia antigen positive sera. Am J Dis Child. 1972 Apr;123(4):303–309. doi: 10.1001/archpedi.1972.02110100035013. [DOI] [PubMed] [Google Scholar]
  3. Alter H. J., Holland P. V., Purcell R. H., Lander J. J., Feinstone S. M., Morrow A. G., Schmidt P. J. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med. 1972 Nov;77(5):691–699. doi: 10.7326/0003-4819-77-5-691. [DOI] [PubMed] [Google Scholar]
  4. Barker L. F., Maynard J. E., Purcell R. H., Hoofnagle J. H., Berquist K. R., London W. T., Gerety R. J., Krushak D. H. Hepatitis B virus infection in chimpanzees: titration of subtypes. J Infect Dis. 1975 Oct;132(4):451–458. doi: 10.1093/infdis/132.4.451. [DOI] [PubMed] [Google Scholar]
  5. Bove J. R. Transfusion-associated hepatitis and AIDS. What is the risk? N Engl J Med. 1987 Jul 23;317(4):242–245. doi: 10.1056/NEJM198707233170411. [DOI] [PubMed] [Google Scholar]
  6. Brummelhuis H. G., Over J., Duivis-Vorst C. C., Wilson-de Stürler L. A., Ates G., Hoek P. J., Reerink-Brongers E. E. Contributions to the optimal use of human blood. IX. Elimination of hepatitis B transmission by (potentially) infectious plasma derivatives. Vox Sang. 1983;45(3):205–216. doi: 10.1111/j.1423-0410.1983.tb01906.x. [DOI] [PubMed] [Google Scholar]
  7. Burnouf T., Martinache L., Goudemand M. L'inactivation des virus dans les fractions plasmatiques à usage thérapeutique. Nouv Rev Fr Hematol. 1987;29(1):93–96. [PubMed] [Google Scholar]
  8. Coombs R. W., Collier A. C., Allain J. P., Nikora B., Leuther M., Gjerset G. F., Corey L. Plasma viremia in human immunodeficiency virus infection. N Engl J Med. 1989 Dec 14;321(24):1626–1631. doi: 10.1056/NEJM198912143212402. [DOI] [PubMed] [Google Scholar]
  9. Coombs R. W., Collier A. C., Allain J. P., Nikora B., Leuther M., Gjerset G. F., Corey L. Plasma viremia in human immunodeficiency virus infection. N Engl J Med. 1989 Dec 14;321(24):1626–1631. doi: 10.1056/NEJM198912143212402. [DOI] [PubMed] [Google Scholar]
  10. Dodd R. Y., Barker L. F. Early markers of HIV-1 infection in plasma donors. JAMA. 1989 Jul 7;262(1):92–93. [PubMed] [Google Scholar]
  11. Gerety R. J., Aronson D. L. Plasma derivatives and viral hepatitis. Transfusion. 1982 Sep-Oct;22(5):347–351. doi: 10.1046/j.1537-2995.1982.22583017454.x. [DOI] [PubMed] [Google Scholar]
  12. Goedert J. J., Kessler C. M., Aledort L. M., Biggar R. J., Andes W. A., White G. C., 2nd, Drummond J. E., Vaidya K., Mann D. L., Eyster M. E. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989 Oct 26;321(17):1141–1148. doi: 10.1056/NEJM198910263211701. [DOI] [PubMed] [Google Scholar]
  13. Goedert J. J., Sarngadharan M. G., Eyster M. E., Weiss S. H., Bodner A. J., Gallo R. C., Blattner W. A. Antibodies reactive with human T cell leukemia viruses in the serum of hemophiliacs receiving factor VIII concentrate. Blood. 1985 Feb;65(2):492–495. [PubMed] [Google Scholar]
  14. Gomperts E. D. Procedures for the inactivation of viruses in clotting factor concentrates. Am J Hematol. 1986 Nov;23(3):295–305. doi: 10.1002/ajh.2830230315. [DOI] [PubMed] [Google Scholar]
  15. Ho D. D., Moudgil T., Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989 Dec 14;321(24):1621–1625. doi: 10.1056/NEJM198912143212401. [DOI] [PubMed] [Google Scholar]
  16. Horowitz B., Wiebe M. E., Lippin A., Stryker M. H. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion. 1985 Nov-Dec;25(6):516–522. doi: 10.1046/j.1537-2995.1985.25686071422.x. [DOI] [PubMed] [Google Scholar]
  17. Horowitz M. S., Rooks C., Horowitz B., Hilgartner M. W. Virus safety of solvent/detergent-treated antihaemophilic factor concentrate. Lancet. 1988 Jul 23;2(8604):186–189. doi: 10.1016/s0140-6736(88)92288-x. [DOI] [PubMed] [Google Scholar]
  18. Kleinman S., Secord K. Risk of human immunodeficiency virus (HIV) transmission by anti-HIV negative blood. Estimates using the lookback methodology. Transfusion. 1988 Sep-Oct;28(5):499–501. doi: 10.1046/j.1537-2995.1988.28588337347.x. [DOI] [PubMed] [Google Scholar]
  19. Levy J. A., Mitra G. A., Wong M. F., Mozen M. M. Inactivation by wet and dry heat of AIDS-associated retroviruses during factor VIII purification from plasma. Lancet. 1985 Jun 22;1(8443):1456–1457. doi: 10.1016/s0140-6736(85)91888-4. [DOI] [PubMed] [Google Scholar]
  20. Ludlam C. A., Tucker J., Steel C. M., Tedder R. S., Cheingsong-Popov R., Weiss R. A., McClelland D. B., Philp I., Prescott R. J. Human T-lymphotropic virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet. 1985 Aug 3;2(8449):233–236. doi: 10.1016/s0140-6736(85)90288-0. [DOI] [PubMed] [Google Scholar]
  21. Mannucci P. M., Colombo M. Virucidal treatment of clotting factor concentrates. Lancet. 1988 Oct 1;2(8614):782–785. doi: 10.1016/s0140-6736(88)92426-9. [DOI] [PubMed] [Google Scholar]
  22. Melief C. J., Goudsmit J. Transmission of lymphotropic retroviruses (HTLV-I and LAV/HTLV-III) by blood transfusion and blood products. Vox Sang. 1986;50(1):1–11. doi: 10.1111/j.1423-0410.1986.tb04837.x. [DOI] [PubMed] [Google Scholar]
  23. Peterman T. A., Lui K. J., Lawrence D. N., Allen J. R. Estimating the risks of transfusion-associated acquired immune deficiency syndrome and human immunodeficiency virus infection. Transfusion. 1987 Sep-Oct;27(5):371–374. doi: 10.1046/j.1537-2995.1987.27587320525.x. [DOI] [PubMed] [Google Scholar]
  24. Peterman T. A., Lui K. J., Lawrence D. N., Allen J. R. Estimating the risks of transfusion-associated acquired immune deficiency syndrome and human immunodeficiency virus infection. Transfusion. 1987 Sep-Oct;27(5):371–374. doi: 10.1046/j.1537-2995.1987.27587320525.x. [DOI] [PubMed] [Google Scholar]
  25. Piszkiewicz D., Sun C. S., Tondreau S. C. Inactivation and removal of human immunodeficiency virus in monoclonal purified antihemophilic factor (human) (Hemofil M). Thromb Res. 1989 Sep 1;55(5):627–634. doi: 10.1016/0049-3848(89)90395-2. [DOI] [PubMed] [Google Scholar]
  26. Piët M. P., Chin S., Prince A. M., Brotman B., Cundell A. M., Horowitz B. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion. 1990 Sep;30(7):591–598. doi: 10.1046/j.1537-2995.1990.30790385516.x. [DOI] [PubMed] [Google Scholar]
  27. Prince A. M., Horowitz B., Brotman B. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet. 1986 Mar 29;1(8483):706–710. doi: 10.1016/s0140-6736(86)91101-3. [DOI] [PubMed] [Google Scholar]
  28. Prince A. M., Horowitz B., Horowitz M. S., Zang E. The development of virus-free labile blood derivatives--a review. Eur J Epidemiol. 1987 Jun;3(2):103–118. doi: 10.1007/BF00239746. [DOI] [PubMed] [Google Scholar]
  29. Ragni M. V., Tegtmeier G. E., Levy J. A., Kaminsky L. S., Lewis J. H., Spero J. A., Bontempo F. A., Handwerk-Leber C., Bayer W. L., Zimmerman D. H. AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations. Blood. 1986 Mar;67(3):592–595. [PubMed] [Google Scholar]
  30. Robinson W. S., Lutwick L. I. The virus of hepatitis, type B. (Second of two parts). N Engl J Med. 1976 Nov 25;295(22):1232–1236. doi: 10.1056/NEJM197611252952206. [DOI] [PubMed] [Google Scholar]
  31. Roeckel I. E. The blood supply--safer than it has ever been. Transfusion. 1989 Mar-Apr;29(3):276–276. doi: 10.1046/j.1537-2995.1989.29389162738.x. [DOI] [PubMed] [Google Scholar]
  32. Schnittman S. M., Psallidopoulos M. C., Lane H. C., Thompson L., Baseler M., Massari F., Fox C. H., Salzman N. P., Fauci A. S. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science. 1989 Jul 21;245(4915):305–308. doi: 10.1126/science.2665081. [DOI] [PubMed] [Google Scholar]
  33. Schorr J. B., Berkowitz A., Cumming P. D., Katz A. J., Sandler S. G. Prevalence of HTLV-III antibody in American blood donors. N Engl J Med. 1985 Aug 8;313(6):384–385. doi: 10.1056/NEJM198508083130610. [DOI] [PubMed] [Google Scholar]
  34. Schorr J. B., Berkowitz A., Cumming P. D., Katz A. J., Sandler S. G. Prevalence of HTLV-III antibody in American blood donors. N Engl J Med. 1985 Aug 8;313(6):384–385. doi: 10.1056/NEJM198508083130610. [DOI] [PubMed] [Google Scholar]
  35. Schroeder D. D., Mozen M. M. Australia antigen: distribution during Cohn ethanol fractionation of human plasma. Science. 1970 Jun 19;168(3938):1462–1464. doi: 10.1126/science.168.3938.1462. [DOI] [PubMed] [Google Scholar]
  36. Shikata T., Karasawa T., Abe K., Takahashi T., Mayumi M., Oda T. Incomplete inactivation of hepatitis B virus after heat treatment at 60 C for 10 hours. J Infect Dis. 1978 Aug;138(2):242–244. doi: 10.1093/infdis/138.2.242. [DOI] [PubMed] [Google Scholar]
  37. Szmuness W., Hirsch R. L., Prince A. M., Levine R. W., Harley E. J., Ikram H. Hepatitis B surface antigen in blood donors: further observations. J Infect Dis. 1975 Feb;131(2):111–118. doi: 10.1093/infdis/131.2.111. [DOI] [PubMed] [Google Scholar]
  38. Tabor E., Purcell R. H., Gerety R. J. Primate animal models and titered inocula for the study of human hepatitis A, hepatitis B, and non-A, non-B hepatitis. J Med Primatol. 1983;12(6):305–318. [PubMed] [Google Scholar]
  39. Trepo C., Hantz O., Jacquier M. F., Nemoz G., Cappel R., Trepo D. Different fates of hepatitis B virus markers during plasma fractionation: a clue to the infectivity of blood derivatives. Vox Sang. 1978 Sep;35(3):143–148. doi: 10.1111/j.1423-0410.1978.tb02913.x. [DOI] [PubMed] [Google Scholar]
  40. Ward J. W., Holmberg S. D., Allen J. R., Cohn D. L., Critchley S. E., Kleinman S. H., Lenes B. A., Ravenholt O., Davis J. R., Quinn M. G. Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. N Engl J Med. 1988 Feb 25;318(8):473–478. doi: 10.1056/NEJM198802253180803. [DOI] [PubMed] [Google Scholar]
  41. Weiner A. J., Kuo G., Bradley D. W., Bonino F., Saracco G., Lee C., Rosenblatt J., Choo Q. L., Houghton M. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet. 1990 Jan 6;335(8680):1–3. doi: 10.1016/0140-6736(90)90134-q. [DOI] [PubMed] [Google Scholar]
  42. Wells M. A., Wittek A. E., Epstein J. S., Marcus-Sekura C., Daniel S., Tankersley D. L., Preston M. S., Quinnan G. V., Jr Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion. 1986 Mar-Apr;26(2):210–213. doi: 10.1046/j.1537-2995.1986.26286152919.x. [DOI] [PubMed] [Google Scholar]
  43. Zuck T. F., Sherwood W. C., Bove J. R. A review of recent events related to surrogate testing of blood to prevent non-A, non-B posttransfusion hepatitis. Transfusion. 1987 Mar-Apr;27(2):203–206. doi: 10.1046/j.1537-2995.1987.27287150202.x. [DOI] [PubMed] [Google Scholar]
  44. van der Poel C. L., Reesink H. W., Schaasberg W., Leentvaar-Kuypers A., Bakker E., Exel-Oehlers P. J., Lelie P. N. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet. 1990 Mar 10;335(8689):558–560. doi: 10.1016/0140-6736(90)90347-8. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES